Pharmacology Review: Using Modeling and Simulation for Neonatal Drug Development

In recent years, there has been an increasing use of modeling and simulation (M&S) within the pharmaceutical industry, along with increasing acceptance of M&S in pediatric drug development by regulatory agencies. Moreover, an increasing body of physiologic, biological, and pharmacologic data has become available to inform neonatal modeling. Developing complementary M&S frameworks for neonates is warranted to support first-in-neonate dose selection and expedite successful neonatal drug development.

Source: NeoReviews recent issues - November 2, 2015 Category: Pediatrics Authors: Wang, J., Edginton, A. N., Burckart, G. Tags: Pediatric Drug Labeling Update Articles Source Type: news